<DOC>
	<DOCNO>NCT01420003</DOCNO>
	<brief_summary>The purpose study characterize time course B cell activation allergen challenge , specifically measure M1 prime related biomarkers .</brief_summary>
	<brief_title>Kinetics IgE Memory B Cells , Plasmablasts Plasma Cells After Whole Lung Allergen Challenge Mild Asthmatics</brief_title>
	<detailed_description>M1 prime segment IgE find membrane form IgE soluble IgE find serum . Membrane IgE ( M1prime ) express IgE-switched B cell , IgE-memory B cels , IgE-plasmablasts . Depletion IgE-switched B cell plasmablasts reduce IgE-producing cell serum IgE , may target treatment allergic asthma . A humanized antibody target M1 prime develop Genentech , Inc. , potential therapeutic asthma . Currently , efficacy MEMP1972A assess allergen challenge study mild asthmatic ( MOP4843g ) . Extensive biomarker sample incorporate study characterize mechanism action ( MOA ) well kinetics MOA MEMP1972A , poorly understood time . Furthermore , sample B cell enrich peripheral blood flow cytometry bone marrow aspirate evaluate kinetics MOA MEMP1972a collect 24 hr allergen challenge due visit sample volume limitation . It know maximal B cell response expect ~7 day allergen stimulation . Therefore , purpose research study characterize time course B cell activation allergen challenge , specifically measure M1 prime related biomarkers .</detailed_description>
	<criteria>Male female volunteer 18 65 year age . Females must actively seek pregnancy , must use adequate effective contraception General good health Mild moderate , stable , allergic asthma History episodic wheeze shortness breath ; FEV1 baseline least 70 % predict value Able understand give write informed consent sign write informed consent form approve investigator 's REB Positive methacholine challenge Positive skinprick test common aeroallergens ( include cat , dust mite , grass , pollen ) Positive allergeninduced airway bronchoconstriction ( fall FEV1 least 20 % baseline ) A worsen asthma respiratory tract infection within 6 week precede study entry History clinically significant hypotensive episode symptom faint , dizziness , lightheadedness History symptom clinically significant autoimmune disease History clinically significant hematologic abnormality , include coagulopathy Be pregnant lactating Use corticosteroid , immunosuppressive , anticoagulant ( warfarin heparin ) within 28 day prior randomization study Use nonsteroidal antiinflammatory drug ( NSAIDs ) within 48 hour dose aspirin 7 day dose Have chronic use medication treatment allergic lung disease short intermediateacting ÃŸ2agonists ipratropium bromide Use caffeinecontaining product medication 12 hour alcohol counter drug include aspirin , cold allergy medication 48 hour inhale bronchodilator 8 hour prior methacholine allergen challenge Use tobacco product kind currently within previous 12 month , smoke history &gt; 10 pack year . Lung disease mild moderate allergic asthma Unwillingness inability comply study protocol reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Allergen Challenge</keyword>
	<keyword>B cell activation</keyword>
	<keyword>M1 prime relate biomarkers</keyword>
</DOC>